2. Signaling Pathways
  3. Epigenetics
  4. Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA)

Small Interfering RNA (siRNA) is a small exogenous double-stranded RNA (dsRNA) (20-25 nucleotides), which triggers the RNA interference (RNAi) pathway. The short dsRNA unwinds and the sense strand is degraded. Antisense strand forms RNA induced silencing complex (RISC) with various protein components. The antisense strand retained in RISC is specifically complementary to the target gene mRNA. Meanwhile, RISC has nuclease activity, which can cut and degrade the target gene mRNA, and inhibit the expression of target gene. Incomplete complementarity results in mRNA translation inhibition.

Small Interfering RNA (siRNA) Related Products (29569):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-150223
    GalNAc unconjugated/naked Inclisiran
    GalNAc unconjugated/naked Inclisiran is a double-stranded small interfering RNA molecule that targets hepatic PCSK9 production to reduce LDL-C levels. GalNAc unconjugated/naked Inclisiran can be used in the research of cardiovascular diseases and hypercholesterolemia.
    GalNAc unconjugated/naked Inclisiran
  • HY-132590A
    Revusiran sodium
    		Inhibitor
    Revusiran (ALN-TTRSC) sodium is an RNA interference agent targeting the mRNA of transthyretin (Transthyretin, TTR). Revusiran sodium mediates sequence-specific degradation of TTR mRNA through RNA interference, reduces the synthesis of TTR protein, binds to GalNAc ligands, and is taken up by hepatocytes via the asialoglycoprotein receptor. Revusiran sodium exhibits favorable nonclinical safety profiles. Revusiran sodium can be used in studies related to transthyretin-mediated amyloidosis.
    Revusiran sodium
  • HY-147266
    Elebsiran sodium
    Elebsiran (VIR-2218) sodium is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran sodium leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran sodium binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran sodium can be used for the study of chronic HBV/HDV infections.
    Elebsiran sodium
  • HY-RS13702
    SPP1 Human Pre-designed siRNA Set A
    		Pre-designed Set

    SPP1 Human Pre-designed siRNA Set A contains three designed siRNAs for SPP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SPP1 Human Pre-designed siRNA Set A
  • HY-145720
    Cemdisiran
    		98.43%
    Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
    Cemdisiran
  • HY-RS06168
    HIF1A Human Pre-designed siRNA Set A
    		Pre-designed Set

    HIF1A Human Pre-designed siRNA Set A contains three designed siRNAs for HIF1A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    HIF1A Human Pre-designed siRNA Set A
  • HY-153492A
    Olpasiran sodium
    		Inhibitor 98.82%
    Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis.
    Olpasiran sodium
  • HY-P990053
    Nelistotug
    Nelistotug (GSK 6097608; GSK6097608) is a human IgG1κ antibody targeting CD96.
    Nelistotug
  • HY-RS12937
    SIRT1 Human Pre-designed siRNA Set A
    		Pre-designed Set

    SIRT1 Human Pre-designed siRNA Set A contains three designed siRNAs for SIRT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SIRT1 Human Pre-designed siRNA Set A
  • HY-132587A
    Fitusiran sodium
    Fitusiran (ALN-AT3SC) sodium is a siRNA strategy. Fitusiran delivers siRNA targeting the SERPINC1 gene in hepatocytes to inhibit antithrombin synthesis. Fitusiran sodium enhances thrombin activity and increases Thrombin generation, thereby restoring hemostatic function. Fitusiran sodium can be used in hemophilia-related research.
    Fitusiran sodium
  • HY-RS01129
    ATF3 Human Pre-designed siRNA Set A
    		Pre-designed Set

    ATF3 Human Pre-designed siRNA Set A contains three designed siRNAs for ATF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    ATF3 Human Pre-designed siRNA Set A
  • HY-RS13325
    SLC7A11 Human Pre-designed siRNA Set A
    		Pre-designed Set

    SLC7A11 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC7A11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SLC7A11 Human Pre-designed siRNA Set A
  • HY-RS13886
    STAT1 Human Pre-designed siRNA Set A
    		Pre-designed Set

    STAT1 Human Pre-designed siRNA Set A contains three designed siRNAs for STAT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    STAT1 Human Pre-designed siRNA Set A
  • HY-RS15958
    ZBP1 Human Pre-designed siRNA Set A
    		Pre-designed Set

    ZBP1 Human Pre-designed siRNA Set A contains three designed siRNAs for ZBP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    ZBP1 Human Pre-designed siRNA Set A
  • HY-153609
    AS-Patisiran sodium
    AS-Patisiran sodium is an antisense strand of Patisiran. Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis.
    AS-Patisiran sodium
  • HY-RS16219
    SPP1 Mouse Pre-designed siRNA Set A
    		Pre-designed Set

    SPP1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for SPP1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SPP1 Mouse Pre-designed siRNA Set A
  • HY-RS09245
    NFE2L2 Human Pre-designed siRNA Set A
    		Pre-designed Set

    NFE2L2 Human Pre-designed siRNA Set A contains three designed siRNAs for NFE2L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    NFE2L2 Human Pre-designed siRNA Set A
  • HY-RS13888
    STAT3 Human Pre-designed siRNA Set A
    		Pre-designed Set

    STAT3 Human Pre-designed siRNA Set A contains three designed siRNAs for STAT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    STAT3 Human Pre-designed siRNA Set A
  • HY-RS06902
    IRF1 Human Pre-designed siRNA Set A
    		Pre-designed Set

    IRF1 Human Pre-designed siRNA Set A contains three designed siRNAs for IRF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    IRF1 Human Pre-designed siRNA Set A
  • HY-RS07572
    LDHB Human Pre-designed siRNA Set A
    		Pre-designed Set

    LDHB Human Pre-designed siRNA Set A contains three designed siRNAs for LDHB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    LDHB Human Pre-designed siRNA Set A